ERBB2 and breast cancer: Traditionally, molecular testing for a relatively small panel of genes was conducted in a histologically-defined subset of patients to determine therapy (e.g. BRAF mutation testing in patients with melanoma, HER2 immunohistochemical staining in patients with breast cancer).